Skip to main content
. 2016 Jun 8;9:3443–3450. doi: 10.2147/OTT.S104431

Table 1.

Patient characteristics

Characteristics XEC (n=61) FEC (n=70) P-value*
Number of patients
 Enrolled 63 74 0.689
 Dropouts 2 4
Age (years)
 Median (range) 43 (19–68) 42 (21–69) 0.215
ECOG performance status
 0 39 44 0.898
 1 22 26
Clinical T-stage
  ≥5 cm 35 39 0.848
 <5 cm 26 31
Pathological pattern
 Invasive ductal carcinoma 47 53 0.570
 Mucinous carcinoma 2 1
 Cribriform carcinoma 1 0
Clinical N-stage
 N1 28 35 0.842
 N2 23 23
 N3 10 12
HR
 Positive 39 45 0.967
 Negative 22 25
HER2
 Positive 17 21 0.814
 Negative 41 44
 Unknown 3 5
Molecular type
 Triple negative 12 11 0.553
 Non-triple negative 49 59

Notes:

*

P-value by chi-square test or Fisher’s exact test when the cell expectation was less than six; for comparison of age distribution 2 sample, t-test was used. Her-2(+)meant it was positive in FISH or CISH test or (+++) in ICH test according to NCCN in 2011. In 2010, guidance for investigations of ER and PR in breast cancer was developed by ASCO and CAP where professors recommended that the positive criteria of ER and PR were ≥1% of positive nuclear staining.

Abbreviations: ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; CISH, chromogenic in situ hybridization; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; FEC, 5-FU/epirubicin/cyclophosphamide; 5-FU, 5-fluorouracil; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; ICH, immunohistochemistry; NCCN, National Comprehensive Cancer Network; PR, progesterone receptor; XEC, capecitabine/epirubicin/cyclophosphamide.